Gilteritinib
Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC50s of 0.29 nM/0.73 nM, respectively.
Product Specifications
CAS Number
1254053-43-4
Product Name Alternative
ASP2215
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
FLT3; TAM Receptor
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Gilteritinib.html
Purity
99.84
Solubility
DMSO : 2 mg/mL (ultrasonic) |Ethanol : 100 mg/mL (ultrasonic; adjust pH to 2 with HCl)
Smiles
NC(C1=NC(CC)=C(NC2CCOCC2)N=C1NC3=CC(OC)=C(N4CCC(N5CCN(C)CC5)CC4)C=C3)=O
Molecular Formula
C29H44N8O3
Molecular Weight
552.71
Precautions
H315, H319, H335
References & Citations
[1]ASP2215, a novel FLT3/AXL inhibitor: Preclinical evaluation in acute myeloid leukemia (AML) . 2014 ASCO Annual Meeting.|[2]Mori M, et al. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Invest New Drugs. 2017 Oct;35 (5) :556-565.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
Axl
Citation 01
Acta Biomater. 2024 Sep 3:S1742-7061 (24) 00505-1.|Autophagy. 2025 Apr 10:1-20.|Bioengineering (Basel) . 2025 Oct 19;12 (10) :1121.|Biomed Pharmacother. 2023 Sep:165:115066.|Biomed Pharmacother. 2024 Oct 28:180:117603.|bioRxiv. 2025 May 29.|Blood Cancer J. 2022 Jan 11;12 (1) :5.|Blood Cancer J. 2025 Mar 15;15 (1) :40.|Cancer Cell Int. 2020 Jun 17;20:250.|Cancer Cell. 2024 Nov 11;42 (11) :1955-1969.e7.|Cancer Discov. 2023 Jul 7;13 (7) :1720-1747.|Cancer Lett. 2024 Jun 28:592:216933.|Cancer Res Commun. 2024 Feb 16;4 (2) :431-445.|Cancers. 2020 Aug 19;12 (9) :2341.|Cancers. 2020 Jun 14;12 (6) :1574.|Cell Biol Toxicol. 2024 Nov 28;40 (1) :105.|Cell Rep Med. 2024 Jul 16;5 (7) :101645.|Cell Rep. 2024 Sep 25:114774.|Comput Biol Med. 2024 Feb:169:107889.|Department of Pharmacology & Toxicology. 2020 Jul.|Expert Rev Clin Immunol. 2025 Jun 25:1-11.|Front Pharmacol. 2021 Mar 8;12:644342.|Haematologica. 2018 Nov;103 (11) :1862-1872.|J Control Release. 2024 Mar:367:821-836.|J Control Release. 2025 Jun 5:113934.|J Oncol. 2021 Sep 21:2021:3766428.|Mol Cancer Res. 2022 Feb;20 (2) :293-304.|Mol Pharmacol. 2022 Jun;101 (6) :381-389.|Mol Syst Biol. 2024 Jan;20 (1) :28-55.|Nat Cancer. 2024 Jul;5 (7) :1082-1101.|Pharm Res. 2025 Sep;42 (9) :1497-1509.|Polymers. 2024 Jan 12;16 (2) :225.|Research Square Preprint. 2023 Dec 6.|Sci Adv. 2022 Sep 16;8 (37) :eabp9005.|Sci Rep. 2021 Mar 11;11 (1) :5715.|Science. 2017 Dec 1;358 (6367) :eaan4368.|Separations. 2023 Apr 25, 10 (5), 278.|Target Oncol. 2022 Nov;17 (6) :695-707.|Blood Cancer Discov. 2022 May 5;3 (3) :240-263.|Eur J Med Chem. 2022 Jul 5;237:114356.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
